Evenity
Evenity is the brand name for romosozumab, a monoclonal antibody used to treat osteoporosis in postmenopausal women at high risk of fracture. It is developed by Amgen and works by inhibiting sclerostin, a protein that restrains bone formation. By blocking sclerostin, romosozumab stimulates bone formation and, to a lesser extent, reduces bone resorption, leading to increases in bone mineral density at the spine and hip.
Romosozumab is administered as a subcutaneous injection once a month for 12 consecutive months. The total duration
Clinical trials showed that romosozumab reduces fracture risk and increases bone density compared with placebo or
Commonly used with caution and proper monitoring, Evenity represents a targeted option for osteoporosis management in